These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 33240257)

  • 1. The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity.
    Keshtkar-Jahromi M; Reisler RB; Haller JM; Clizbe DP; Rivard RG; Cardile AP; Pierson BC; Norris S; Saunders D; Pittman PR
    Front Immunol; 2020; 11():555464. PubMed ID: 33240257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of an inactivated eastern equine encephalitis virus vaccine.
    Pierson BC; Cardile AP; Okwesili AC; Downs IL; Reisler RB; Boudreau EF; Kortepeter MG; Koca CD; Ranadive MV; Petitt PL; Kanesa-Thasan N; Rivard RG; Liggett DL; Haller JM; Norris SL; Purcell BK; Pittman PR; Saunders DL; Keshtkar Jahromi M
    Vaccine; 2021 May; 39(20):2780-2790. PubMed ID: 33888325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune interference in the setting of same-day administration of two similar inactivated alphavirus vaccines: eastern equine and western equine encephalitis.
    Reisler RB; Gibbs PH; Danner DK; Boudreau EF
    Vaccine; 2012 Nov; 30(50):7271-7. PubMed ID: 23031498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study.
    Rusnak JM; Gibbs P; Boudreau E; Clizbe DP; Pittman P
    Vaccine; 2011 Apr; 29(17):3222-9. PubMed ID: 21354483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine.
    Pittman PR; Makuch RS; Mangiafico JA; Cannon TL; Gibbs PH; Peters CJ
    Vaccine; 1996 Mar; 14(4):337-43. PubMed ID: 8744562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
    Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term immunogenicity and safety of inactivated Hantaan virus vaccine (Hantavax™) in healthy adults.
    Song JY; Woo HJ; Cheong HJ; Noh JY; Baek LJ; Kim WJ
    Vaccine; 2016 Mar; 34(10):1289-95. PubMed ID: 26826547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan.
    Huang LM; Chiu CH; Chiu NC; Lin CY; Li MT; Kuo TY; Weng YJ; Hsieh EF; Tai IC
    Vaccine; 2019 Mar; 37(13):1827-1835. PubMed ID: 30803843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial.
    Wressnigg N; van der Velden MV; Portsmouth D; Draxler W; O'Rourke M; Richmond P; Hall S; McBride WJ; Redfern A; Aaskov J; Barrett PN; Aichinger G
    Clin Vaccine Immunol; 2015 Mar; 22(3):267-73. PubMed ID: 25540268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience.
    Pittman PR; Liu CT; Cannon TL; Makuch RS; Mangiafico JA; Gibbs PH; Peters CJ
    Vaccine; 1999 Aug; 18(1-2):181-9. PubMed ID: 10501248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial.
    Aichinger G; Ehrlich HJ; Aaskov JG; Fritsch S; Thomasser C; Draxler W; Wolzt M; Müller M; Pinl F; Van Damme P; Hens A; Levy J; Portsmouth D; Holzer G; Kistner O; Kreil TR; Barrett PN
    Vaccine; 2011 Nov; 29(50):9376-84. PubMed ID: 22001875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine.
    Cheng A; Fung CP; Liu CC; Lin YT; Tsai HY; Chang SC; Chou AH; Chang JY; Jiang RH; Hsieh YC; Su IJ; Chong PC; Hsieh SM
    Vaccine; 2013 May; 31(20):2471-6. PubMed ID: 23541623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.
    Overton ET; Lawrence SJ; Wagner E; Nopora K; Rösch S; Young P; Schmidt D; Kreusel C; De Carli S; Meyer TP; Weidenthaler H; Samy N; Chaplin P
    PLoS One; 2018; 13(4):e0195897. PubMed ID: 29652929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3-6 years and 2-35 months of age- an open-label, randomized phase IIb clinical trial.
    Hung MC; Cho CY; Chen CJ; Lai CC; Wu KG
    Vaccine; 2019 Sep; 37(37):5559-5566. PubMed ID: 31399275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
    Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
    Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens.
    Defraites RF; Gambel JM; Hoke CH; Sanchez JL; Withers BG; Karabatsos N; Shope RE; Tirrell S; Yoshida I; Takagi M; Meschievitz CK; Tsai TF
    Am J Trop Med Hyg; 1999 Aug; 61(2):288-93. PubMed ID: 10463681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine.
    Engler RJ; Mangiafico JA; Jahrling P; Ksiazek TG; Pedrotti-Krueger M; Peters CJ
    J Med Virol; 1992 Dec; 38(4):305-10. PubMed ID: 1474379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.